Costrini N V, Beck R
Cancer. 1983 Jun 15;51(12):2191-6. doi: 10.1002/1097-0142(19830615)51:12<2191::aid-cncr2820511207>3.0.co;2-q.
Epidermal growth factor-urogastrone (EGF-URO) receptors have been demonstrated in rodent liver and modulation of ligand binding during transformation has been shown in a variety of study systems. A patient presented with a resectable primary hepatoma arising in a histologically normal liver. We carried out ligand binding studies using 125I-EGF and homogenates or plasma membrane preparations of normal and hepatoma tissues. EGF-URO receptors were demonstrated in normal human liver; half-maximal binding occurred at 2.5 X 10(-9) M 125I-EGF. Binding decreased in association with hepatoma formation. These results provide initial evidence that EGF-URO receptors exist in human liver and that ligand binding changes accompany hepatoma formation in man.
表皮生长因子-尿抑胃素（EGF-URO）受体已在啮齿动物肝脏中得到证实，并且在多种研究系统中均显示出在转化过程中配体结合的调节作用。一名患者的原发性肝癌可切除，其肝脏组织学正常。我们使用125I-EGF以及正常组织和肝癌组织的匀浆或质膜制剂进行了配体结合研究。在正常人类肝脏中证实了EGF-URO受体；半最大结合发生在2.5×10^(-9)M 125I-EGF时。随着肝癌形成，结合减少。这些结果提供了初步证据，表明人肝脏中存在EGF-URO受体，并且在人类肝癌形成过程中配体结合发生变化。
